Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prudence A Russell

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Thorax|July 24, 2013
The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancerMuhammad Alamgeer, Vinod Ganju, Anette Szczepny, et al.
Cancer Cytopathology|May 4, 2019
Immunocytochemistry for predictive biomarker testing in lung cancer cytologyDeepali Jain, Aruna Nambirajan, Alain Borczuk, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2015
Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancerToni-Maree Rogers, Prudence A Russell, Gavin Wright, et al.
Pathology|November 1, 2019
Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancerNick Pavlakis, Caroline Cooper, Thomas John, et al.
Oncotarget|November 2, 2017
Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancerAnderly C Chüeh, Mun-Sem Liew, Prudence A Russell, et al.
Oncogene|October 22, 2021
Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epitheliumJasmine Chen, Aleks Guanizo, Quinton Luong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2017
Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung CancerWendy A Cooper, Prudence A Russell, Maya Cherian, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 8, 2013
Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridizationChristina I Selinger, Toni-Maree Rogers, Prudence A Russell, et al.
Oral Oncology|February 26, 2013
Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcomeRichard J Young, Annette M Lim, Christopher Angel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 25, 2022
NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell CarcinomaDeepali Jain, Aruna Nambirajan, Gang Chen, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Thorax|July 24, 2013
The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancerMuhammad Alamgeer, Vinod Ganju, Anette Szczepny, et al.
Cancer Cytopathology|May 4, 2019
Immunocytochemistry for predictive biomarker testing in lung cancer cytologyDeepali Jain, Aruna Nambirajan, Alain Borczuk, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2015
Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancerToni-Maree Rogers, Prudence A Russell, Gavin Wright, et al.
Pathology|November 1, 2019
Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancerNick Pavlakis, Caroline Cooper, Thomas John, et al.
Oncotarget|November 2, 2017
Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancerAnderly C Chüeh, Mun-Sem Liew, Prudence A Russell, et al.
Oncogene|October 22, 2021
Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epitheliumJasmine Chen, Aleks Guanizo, Quinton Luong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2017
Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung CancerWendy A Cooper, Prudence A Russell, Maya Cherian, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 8, 2013
Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridizationChristina I Selinger, Toni-Maree Rogers, Prudence A Russell, et al.
Oral Oncology|February 26, 2013
Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcomeRichard J Young, Annette M Lim, Christopher Angel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 25, 2022
NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell CarcinomaDeepali Jain, Aruna Nambirajan, Gang Chen, et al.
Pageof 6